OCBC 4Q Net Rose on Lower Allowance, Raises Dividend Payout
By P.R. Venkat
Oversea-Chinese Banking Corp.'s fourth-quarter profit rose because of lower allowances and higher contributions from non-interest income.
Net profit rose 12% from a year earlier to 1.62 billion Singapore dollars ($1.21 billion), OCBC said Wednesday.
Total income during the period expanded 8% to S$3.27 billion, while net interest income rose 3% to S$2.46 billion. Non-net interest income came in at S$811.0 million, compared with S$646.0 million a year earlier.
Allowances for loans and other assets during the quarter were S$187 million, down from S$314 million.
The board increased the dividend payout, which will see the bank pay 82 Singapore cents a share as a dividend for 2023 compared with 68 Singapore cents a share the previous year.
This will translate to a payout ratio of 53% of the group's 2023 net profit.
"Looking ahead, we anticipate challenges in the global macro environment, including changes in monetary policies, persistent inflationary pressures, major elections and rising geopolitical tensions," Chief Executive Helen Wong said.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
February 27, 2024 19:01 ET (00:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks